Table 1.

EGFR and VEGFR-2 kinases inhibitory activity of target thiazolyl-pyrazoline derivatives.

Compound	R	R1	IC50 (nM) ± SEM
			EGFR	VEGFR-2
7a	H	H	145.1 ± 2.0	124.9 ± 1.4
7b	H	Cl	114.2 ± 0.4	195.2 ± 4.6
7c	OCH3	H	511.2 ± 3.2	915.2 ± 4.3
7d	OCH3	Cl	132.9 ± 1.2	185.5 ± 2.3
10a	H	CH3	274.0 ± 2.3	450.3 ± 8.3
10b	H	OCH2CH3	40.7 ± 1.0	78.4 ± 1.5
10c	H	NHC6H5	130.7 ± 1.1	102.2 ± 4.3
10d	OCH3	NHC6H5	32.5 ± 2.2	43.0 ± 2.4
13a	H	H	973.0 ± 2.0	1151.2 ± 4.3
13b	H	CH3	179.4 ± 0.0	214.3 ± 4.0
13c	H	Cl	134.5 ± 1.5	173.3 ± 2.6
13d	OCH3	H	93.6 ± 3.0	335.8 ± 6.3
13e	OCH3	CH3	67.7 ± 2.0	216.4 ± 4.3
13f	OCH3	Cl	107.13 ± 1.2	113.3 ± 1.8
Gefitinib	–	–	55.74 ± 1.0	45.3 ± 1.2
Vandetanib	–	–	43.14 ± 1.3	29.1 ± 1.0